Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Modeling Inflammatory Bowel Disease by Intestinal Organoids

Cristina Di Giorgio
ORCID logo ,
Rosalinda Roselli
,
Michele Biagioli
,
Martina Bordoni
,
Partizia Ricci
,
Angela Zampella
,
Eleonora Distrutti
,
Annibale Donini
,
Stefano Fiorucci
*
Version 1 : Received: 31 March 2022 / Approved: 4 April 2022 / Online: 4 April 2022 (10:35:01 CEST)

A peer-reviewed article of this Preprint also exists.

Giorgio, C.D.; Roselli, R.; Biagioli, M.; Bordoni, M.; Ricci, P.; Zampella, A.; Distrutti, E.; Donini, A.; Fiorucci, S. Modeling Inflammatory Bowel Disease by Intestinal Organoids. Recent Advances in Inflammation & Allergy Drug Discovery 2023, 17, 39–53, doi:10.2174/2772270817666221121143853. Giorgio, C.D.; Roselli, R.; Biagioli, M.; Bordoni, M.; Ricci, P.; Zampella, A.; Distrutti, E.; Donini, A.; Fiorucci, S. Modeling Inflammatory Bowel Disease by Intestinal Organoids. Recent Advances in Inflammation & Allergy Drug Discovery 2023, 17, 39–53, doi:10.2174/2772270817666221121143853.

Abstract

Inflammatory bowel disease (IBD) is a chronic and relapsing disease caused by a dysregulated immune response to host intestinal microbiota that occurs in genetically predisposed individuals. IBD encompasses two major clinical entities: ulcerative colitis (UC), which is limited to the colonic mucosa, and Crohn disease (CD), which might affect any segment of the gastrointestinal tract. Despite the prevalence of IBD is increasing worldwide, therapy remains suboptimal, largely because the variability of causative mechanisms, raising the need to develop individualized therapeutic approaches targeted to each individual patient. In this context, patients-derived intestinal organoids represent an effective tool for advancing our understanding on IBD’ s pathogenesis. Organoid 3D culture systems offer a unique model for dissecting epithelial mechanisms involved IBDs and test individualized therapy, although the lack of a functional immune system and a microbiota, two driving components of the IBD pathogenesis, represent a major barrier for their exploitation in clinical medicine. In this review we have examined how to improve the translational utility of intestinal organoids in IBD and how co-coltures of 3D or 2D organoids and immune cells and/or intestinal microbiota might help to overcome these limitations.

Keywords

Organoids; IBD; Inflammation; Target therapy; microbiota; immune system

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.